BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 38063231)

  • 1. Euphorbia factor L2 suppresses the generation of liver metastatic ascites in breast cancer via inhibiting NLRP3 inflammasome activation.
    Jiang D; Liu X; Tan R; Zhu Y; Zhang L
    Int J Mol Med; 2024 Jan; 53(1):. PubMed ID: 38063231
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Euphorbia factor L1 suppresses breast cancer liver metastasis via DDR1-mediated immune infiltration.
    Jiang D; Gao X; Tan R; Liu X; Zhu Y; Zhang L
    Aging (Albany NY); 2023 Sep; 15(17):9217-9229. PubMed ID: 37709489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Euphorbia factor L2 inhibits TGF-β-induced cell growth and migration of hepatocellular carcinoma through AKT/STAT3.
    Fan L; Zhu H; Tao W; Liu L; Shan X; Zhao M; Sun D
    Phytomedicine; 2019 Sep; 62():152931. PubMed ID: 31085375
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Euphorbia factor L2 alleviates lipopolysaccharide-induced acute lung injury and inflammation in mice through the suppression of NF-κB activation.
    Zhang Q; Zhu S; Cheng X; Lu C; Tao W; Zhang Y; William BC; Cao X; Yi S; Liu Y; Zhao Y; Luo Y
    Biochem Pharmacol; 2018 Sep; 155():444-454. PubMed ID: 30055150
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Alpinumisoflavone suppresses hepatocellular carcinoma cell growth and metastasis via NLRP3 inflammasome-mediated pyroptosis.
    Zhang Y; Yang H; Sun M; He T; Liu Y; Yang X; Shi X; Liu X
    Pharmacol Rep; 2020 Oct; 72(5):1370-1382. PubMed ID: 32301055
    [TBL] [Abstract][Full Text] [Related]  

  • 6. NLR Family Pyrin Domain-Containing 3 Inflammasome Activation in Hepatic Stellate Cells Induces Liver Fibrosis in Mice.
    Inzaugarat ME; Johnson CD; Holtmann TM; McGeough MD; Trautwein C; Papouchado BG; Schwabe R; Hoffman HM; Wree A; Feldstein AE
    Hepatology; 2019 Feb; 69(2):845-859. PubMed ID: 30180270
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Tang J; Cheng X; Yi S; Zhang Y; Tang Z; Zhong Y; Zhang Q; Pan B; Luo Y
    Front Pharmacol; 2021; 12():773592. PubMed ID: 34950033
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hydrogen-Rich Saline Attenuated Subarachnoid Hemorrhage-Induced Early Brain Injury in Rats by Suppressing Inflammatory Response: Possible Involvement of NF-κB Pathway and NLRP3 Inflammasome.
    Shao A; Wu H; Hong Y; Tu S; Sun X; Wu Q; Zhao Q; Zhang J; Sheng J
    Mol Neurobiol; 2016 Jul; 53(5):3462-3476. PubMed ID: 26091790
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mitophagy Induction and Aryl Hydrocarbon Receptor-Mediated Redox Signaling Contribute to the Suppression of Breast Cancer Cell Growth by Taloxifene
    Tran VT; Pham DV; Choi DY; Park PH
    Antioxid Redox Signal; 2022 Nov; 37(13-15):1030-1050. PubMed ID: 35286219
    [No Abstract]   [Full Text] [Related]  

  • 10. Semaglutide attenuates seizure severity and ameliorates cognitive dysfunction by blocking the NLR family pyrin domain containing 3 inflammasome in pentylenetetrazole‑kindled mice.
    Wang L; Ding J; Zhu C; Guo B; Yang W; He W; Li X; Wang Y; Li W; Wang F; Sun T
    Int J Mol Med; 2021 Dec; 48(6):. PubMed ID: 34676876
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Anisodamine Suppressed the Growth of Hepatocellular Carcinoma Cells, Induced Apoptosis and Regulated the Levels of Inflammatory Factors by Inhibiting NLRP3 Inflammasome Activation.
    Li P; Liu Y; He Q
    Drug Des Devel Ther; 2020; 14():1609-1620. PubMed ID: 32425506
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A potential immunotherapy target for breast cancer: parenchymal and immune-stromal expression of the NLRP3 inflammasome pathway.
    Zhu QM; Li HX; Ma PQ; Wu LX; Wang TH; Li WB; Zhang L; Yang X; Kong X; Sun YL; Yan T
    BMC Cancer; 2023 Nov; 23(1):1163. PubMed ID: 38031068
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver kinase B1 attenuates liver ischemia/reperfusion injury via inhibiting the NLRP3 inflammasome.
    Dai J; Chen Q; Huang W; Shi K; Zhang Y; Li T; Mou T; Huang Z; Wu Z
    Acta Biochim Biophys Sin (Shanghai); 2021 Apr; 53(5):601-611. PubMed ID: 33783473
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Coenzyme Q
    Yang HL; Lin PY; Vadivalagan C; Lin YA; Lin KY; Hseu YC
    Arch Toxicol; 2023 Apr; 97(4):1047-1068. PubMed ID: 36847822
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oxymatrine suppresses colorectal cancer progression by inhibiting NLRP3 inflammasome activation through mitophagy induction in vitro and in vivo.
    Liang L; Sun W; Wei X; Wang L; Ruan H; Zhang J; Li S; Zhao B; Li M; Cai Z; Huang J
    Phytother Res; 2023 Aug; 37(8):3342-3362. PubMed ID: 36974424
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Polydatin suppresses proliferation and metastasis of non-small cell lung cancer cells by inhibiting NLRP3 inflammasome activation via NF-κB pathway.
    Zou J; Yang Y; Yang Y; Liu X
    Biomed Pharmacother; 2018 Dec; 108():130-136. PubMed ID: 30218857
    [TBL] [Abstract][Full Text] [Related]  

  • 17. 3,4,5-O-tricaffeoylquinic acid with anti-radiation activity suppresses LPS-induced NLRP3 inflammasome activation via autophagy in THP-1 macrophages.
    Liu J; Chen J; Xu B; Lin L; Liu S; Ma X; Liu J
    Mol Immunol; 2022 Jul; 147():187-198. PubMed ID: 35633614
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Growth of breast cancer cells by leptin is mediated via activation of the inflammasome: Critical roles of estrogen receptor signaling and reactive oxygen species production.
    Raut PK; Kim SH; Choi DY; Jeong GS; Park PH
    Biochem Pharmacol; 2019 Mar; 161():73-88. PubMed ID: 30633869
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Macrophage Sphingosine 1-Phosphate Receptor 2 Blockade Attenuates Liver Inflammation and Fibrogenesis Triggered by NLRP3 Inflammasome.
    Hou L; Yang L; Chang N; Zhao X; Zhou X; Dong C; Liu F; Yang L; Li L
    Front Immunol; 2020; 11():1149. PubMed ID: 32695095
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antcin A alleviates pyroptosis and inflammatory response in Kupffercells of non-alcoholic fatty liver disease by targeting NLRP3.
    Ruan S; Han C; Sheng Y; Wang J; Zhou X; Guan Q; Li W; Zhang C; Yang Y
    Int Immunopharmacol; 2021 Nov; 100():108126. PubMed ID: 34492534
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.